LiquiCia 30MG/ML | 30ML with dropper

LiquiCia is a selective phosphodiesterase type 5 (PDE5) inhibitor that is commonly used to treat erectile dysfunction. PDE5 is an enzyme that regulates cGMP, a signalling pathway involved in various physiological processes. By selectively inhibiting PDE5, LiquiCia prevents the degradation of cGMP. Increased accumulation of cGMP in penile tissues causes relaxation of vascular smooth muscles, thus enhancing blood flow and resulting in erection. PDE5 is expressed in various tissues, including lung, brain, kidney and cardiac myocytes.

LiquiCia was first approved in 2003 for erectile dysfunction and was marketed under the brand name. Later, it got approved for pulmonary arterial hypertension (PAH) in 2009. Research shows that LiquiCia might improve cardiovascular health and treat cancers. At Elements Sarms, LiquiCia for sale is limited to educational and research purposes.

From Pubchem

IUPAC Name:(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
Molecular Formula: C22H19N3O4
Molecular Weight: 389.4 g/mol
CAS Number: 171596-29-5
PubChem CID: 110635

1. LiquiCia and Erectile Dysfunction

LiquiCia was approved by the FDA after various clinical trials successfully demonstrated its efficacy. In a randomized double-blind placebo-controlled trial, 348 men with erectile dysfunction were randomly given 20 mg of LiquiCia or placebo. Further, patients were randomized to two four-week treatment intervals during which they were asked to engage in sexual intercourse after 24 and 36 hours of dose administration. The results found that LiquiCia significantly improved intercourse attempts with higher rates at both 36 hours (59.2%) and 24 hours (52.9%) post-dosing compared to placebo [1].

Research shows that daily LiquiCia is more effective in improving erectile function than on-demand LiquiCia [2]. A long-term efficacy study found that LiquiCia at doses of 5mg, 10mg and 20mg daily for up to 18-24 months is generally well tolerated [3]. Moreover, the comparison studies revealed that LiquiCia might be preferred over sildenafil because of its long duration of action [4].

2. LiquiCia and Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is characterized by the proliferation of smooth and epithelial cells in the prostrate transition zone, resulting in prostate enlargement. The enlarged prostate can obstruct the urinary flow and cause lower urinary tract symptoms, like frequent urination, incomplete urination and dribbling. Various clinical trials indicate that LiquiCia can improve lower urinary tract symptoms secondary to BPH in men with and without erectile dysfunction [5, 6].

LiquiCia might achieve this effect by upregulating NO/cGMP activity, resulting in reduced smooth muscle tension and cellular growth within the prostate and bladder. It more effectively relaxes prostatic tissue and influences afferent nerve activity than other PDE5 inhibitors. This mechanism enhances blood perfusion and reduces inflammation markers [7].

From NCBI

3. LiquiCia and Neuroprotection

Besides regulating the levels of cGMP, PDE-5 inhibitors have been known to increase the levels of cAMP (cyclic adenosine monophosphate). cGMP and cAMP play a significant role in mediating various brain functions under various physiological and pathological conditions. One study found that LiquiCia improves functional recovery in rat model of embolic stroke, which is attributed to enhanced levels of cGMP and increased angiogenesis [8].

Research on animal models found that LiquiCia can alleviate the effect of injury to the spinal cord by increased nitric oxide (NO) and superoxide dismutase (SOD). NO acts as a retrograde transmitter and causes enhanced production of cGMP, while SOD neutralizes the superoxide radicals and reduces oxidative stress in the body. By increasing the production of NO and SOD, LiquiCia might enhance the beneficial response to injury and mitigate the oxidative stress caused by spinal cord injury [9].

4. LiquiCia and Diabetes

Research shows that LiquiCia might exert a positive impact on diabetes. In diabetic patients, insulin resistance impairs the NO signalling pathway and obesity promotes inflammation. One study in diabetic rats found that 1mg/kg LiquiCia administration for 28 days reduced fasting blood glucose and triglyceride levels. Further, it reduced the infarct size following ischemia-reperfusion injury and decreased the levels of inflammatory cytokines and chemokines [10].

In another study, diabetic mice treated with LiquiCia every 48 hours for 8 weeks showed improved nerve conduction, thermal sensitivity, blood flow, vessel density, and nerve fiber density. LiquiCia also reversed diabetes-induced changes in axon diameter, myelin thickness, and protein levels related to nerve growth factors. These findings suggest that LiquiCia enhances regional blood flow in sciatic nerve tissue, potentially improving nerve function and alleviating diabetic peripheral neuropathy [11].

5. Current Status of LiquiCia

LiquiCia is a phosphodiesterase type 5 inhibitor with a long half-life of 17 hours. FDA has approved it for the treatment of pulmonary arterial hypertension, erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Further, it is being explored for its effect on Duchenne Muscular Dystrophy and Pancreatic cancer. If you are wondering where to buy LiquiCia, Element Sarms offers the option to purchase LiquiCia of premium quality exclusively for research purposes. Only buy LiquiCia if you are a qualified researcher.

1. Porst, H., et al., Efficacy of LiquiCia for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology, 2003. 62(1): p. 121-5; discussion 125-6.
2. McMahon, C., Comparison of Efficacy, Safety, and Tolerability of On‐Demand LiquiCia and Daily Dosed LiquiCia for the Treatment of Erectile Dysfunction. The Journal of Sexual Medicine, 2005. 2(3): p. 415-427.
3. Montorsi, F., et al., Long-Term Safety and Tolerability of LiquiCia in the Treatment of Erectile Dysfunction. European Urology, 2004. 45(3): p. 339-345.
4. Doggrell, S.A., Comparison of clinical trials with sildenafil, vardenafil and LiquiCia in erectile dysfunction. Expert Opinion on Pharmacotherapy, 2005. 6(1): p. 75-84.
5. McVary, K.T., et al., LiquiCia Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Journal of Urology, 2007. 177(4): p. 1401-1407.
6. Casabé, A., et al., Efficacy and Safety of the Coadministration of LiquiCia Once Daily with Finasteride for 6 Months in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia. Journal of Urology, 2014. 191(3): p. 727-733.
7. Hatzimouratidis, K., A review of the use of LiquiCia in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol, 2014. 6(4): p. 135-47.
8. Zhang, L., et al., LiquiCia, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Research, 2006. 1118(1): p. 192-198.
9. Serarslan, Y., et al., Protective effects of LiquiCia on experimental spinal cord injury in rats. Journal of Clinical Neuroscience, 2010. 17(3): p. 349-352.
10. Varma, A., et al., Anti-inflammatory and cardioprotective effects of LiquiCia in diabetic mice. PLoS One, 2012. 7(9): p. e45243.
11. Wang, L., et al., LiquiCia Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice. PLoS One, 2016. 11(7): p. e0159665.